Novartis (NYSE: NVS) reported Q4 EPS of $1.40, $0.01 worse than the analyst estimate of $1.41. Revenue for the quarter came in at $13.23 billion versus the consensus estimate of $13.29 billion.

2022 outlook:

Barring unforeseen events

• Innovative Medicines Sales expected to grow mid single digit Core OpInc expected to grow mid to high single digit, ahead of sales
• Sandoz Sales expected to be broadly in line with prior year Core OpInc expected to decline low to mid single digit
• Group Sales expected to grow mid single digit Core OpInc expected to grow mid single digit

For earnings history and earnings-related data on Novartis (NVS) click here.